NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
Overall Response Rate (ORR) of 46% in Patients Receiving the Combination   TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71% ORR)   Long-term Follow Up Shows 11.1 Months Progression Free Survival SEATTLE and SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that management will present at the Piper Jaffray 30 th Annual Healthcare Conference on Tuesday,
View HTML
Toggle Summary Immune Design to Present at Jefferies 2018 London Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya , M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London
View HTML
Toggle Summary Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the third quarter
View HTML
Toggle Summary Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting
New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced
View HTML
Toggle Summary Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
G100 development to accelerate in follicular lymphoma and beyond CMB305 to be deprioritized to support focus on G100 Cash runway extended into 2021 Conference call at 2:00 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an
View HTML
Toggle Summary Immune Design to Present at Upcoming September Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences: 13 th Annual Wells Fargo Securities
View HTML
Toggle Summary Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
G100 advancing to late-stage development following FDA feedback Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S.
View HTML